# iBio Reports Preclinical Data Showing IBIO-610 Helps Preserve Muscle During GLP-1 Weight Loss

- URL: https://stocks.freetheai.org/news/ibio-reports-preclinical-data-showing-ibio-610-helps-preserve-muscle-during-glp-80509b
- Published: 2026-10-13T11:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:IBIO](https://stocks.freetheai.org/symbols/NASDAQ-IBIO)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Biotechnology firm iBio, Inc. (NASDAQ:IBIO) highlighted preclinical data demonstrating that its drug candidate, IBIO-610, reduced lean muscle loss when combined with the weight-loss medication semaglutide. In an eight-week study involving obese non-human primates, animals treated with a combination of IBIO-610 and semaglutide saw fat account for 93% of total weight lost, compared to 77% for those receiving semaglutide alone. Lean mass accounted for only 6% of weight lost under the combination treatment, compared to 22% with semaglutide by itself.

GLP-1 receptor agonists like semaglutide are effective for weight reduction, but patients often experience significant muscle loss alongside fat reduction. IBIO-610 is an Activin E antibody candidate designed to address this issue. In the primate study, a single dose of IBIO-610 reduced active Activin E levels in blood serum by 97% at week eight, demonstrating a 33.2-day half-life in primates that may support twice-yearly dosing in humans.

iBio expects to advance IBIO-610 into first-in-human clinical trials during the first half of 2027. Investors and industry observers will monitor whether these preclinical body-composition results translate into similar outcomes in future human studies.

## Key points

- In an eight-week study on primates, IBIO-610 combined with semaglutide limited lean mass loss to 6% of total weight lost, compared to 22% for semaglutide alone.
- Animals receiving the combination therapy had 93% of their weight loss come from fat, compared with 77% for semaglutide alone.
- A single dose of IBIO-610 achieved a 97% reduction in active Activin E levels at week eight, with a 33.2-day half-life in primates.
- iBio plans to initiate first-in-human clinical trials for IBIO-610 in the first half of 2027.

## Questions and answers

### What is IBIO-610 and how does it work?

IBIO-610 is an Activin E antibody candidate developed by iBio, Inc. to help preserve lean muscle mass when used alongside GLP-1 weight-loss therapies like semaglutide.

### What were the results of the IBIO-610 primate study?

When combined with semaglutide, IBIO-610 reduced lean muscle loss to 6% of total weight lost, compared to 22% for semaglutide alone, with 93% of total loss coming from fat.

### When will clinical trials for IBIO-610 begin?

iBio expects to start first-in-human clinical trials for IBIO-610 in the first half of 2027.